Did you know? You can suggest edits to improve this peptide information.
Overview
What is IGF-1 LR3?
IGF-1 LR3 is a synthetic 83-amino acid analog of human insulin-like growth factor-1 that has never been approved for human use in any country. Despite approximately 3x greater potency than native IGF-1 with a 20-30 hour half-life due to reduced IGF-binding protein interaction, no human clinical trials have ever been conducted. The compound is prohibited in competitive sports, carries significant risks including severe hypoglycemia and cancer proliferation, and remains strictly a research chemical for laboratory use only.
Key Benefits
Approximately 3x more potent than native IGF-1 with 20-30 hour half-life due to reduced IGFBP binding. Promotes both muscle hypertrophy and hyperplasia in animal models.
Mechanism of Action
Full IGF-1 receptor agonist with reduced IGF-binding protein interaction. N-terminal extension and R3 substitution prevent sequestration, maintaining free circulating levels. Activates PI3K/Akt/mTOR and MAPK/ERK pathways.
Research Indications
Muscle Hypertrophy
Animal studies show 15-20% lean mass gains in 4 weeks through satellite cell activation and protein synthesis enhancement. No human data exists.
Anti-Catabolic Effects
Preserves lean mass in cachexia models through ubiquitin-proteasome inhibition. Cancer cachexia rats maintained 30% more muscle versus placebo.
Hyperplasia Induction
Unique ability to create new muscle fibers via satellite cell differentiation, not just enlarging existing fibers. Permanent structural changes possible.
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Post-workout window critical for safety and efficacy. IGF-1 receptors most sensitive when muscles depleted. Must consume carbohydrates immediately to prevent dangerous hypoglycemia lasting up to 30 hours.
Peptide Interactions
How to Reconstitute
Important
Use 0.6% acetic acid. BAC water causes rapid degradation within 2-3 days. Acetic acid maintains stability for 30+ days refrigerated.
Equilibrate vial to room temperature (15-30 min)
Sanitize rubber stopper with alcohol
Calculate concentration (e.g., 1mg in 2mL = 500mcg/mL)
Draw calculated volume of solution
Inject slowly along vial wall, not directly on powder
Gently swirl - never shake vigorously
Allow to dissolve completely (2-5 min)
Store immediately at 2-8°C protected from light
Quality Indicators
Research Chemical Status
Never approved for human use. Zero human clinical trials. All use represents uncontrolled experimentation.
Severe Hypoglycemia Risk
Can cause life-threatening low blood sugar lasting 20-30 hours. Multiple animal deaths documented in studies.
Cancer Proliferation Concern
UK Biobank study links elevated IGF-1 to multiple cancers. May accelerate growth of existing tumors.
Purity Testing Essential
Require HPLC >95% and mass spectrometry confirmation. Black market samples often degraded or contaminated.
Species-Specific Responses
Works in rats, fails in guinea pigs, inhibits growth in pigs. Human response entirely unknown.
Proper Cold Storage Required
Lyophilized powder stable at -20°C. Ships at room temperature but refrigerate immediately upon arrival.
What to Expect
- Week 1-2: Increased pump, fullness, possible hypoglycemia episodes if carbs inadequate
- Week 2-4: Enhanced recovery, strength gains, visible muscle fullness, possible water retention
- Week 4-6: Maximum effects but approaching receptor desensitization. Joint stiffness common.
- Post-cycle: Gradual loss of pumps over 1-2 weeks. Strength/size gains may persist if training maintained.
Side Effects & Safety
- CRITICAL: Consume 30-60g fast carbohydrates immediately after injection
- Never inject before sleep - overnight hypoglycemia risk
- Monitor blood glucose regularly, especially first week
- Contraindicated with any cancer history or undiagnosed growths
- May cause organ hypertrophy (heart, intestines) with prolonged use
- WADA prohibited - will cause failed drug test in athletes
References
Rat Muscle Hypertrophy Study (Florini et al.)
Demonstrated 2.5x greater anabolic response compared to native IGF-1. Satellite cell activation and protein synthesis increased by 50% above baseline. Both hypertrophy and hyperplasia observed.
Fetal Sheep Metabolic Study (Children's Hospital Colorado)
Acute infusion suppressed insulin secretion by 66%. Chronic infusion caused 4 animal deaths from hypoglycemia and hypoxemia. Significantly reduced circulating amino acids, particularly BCAAs.
Pig Growth Inhibition Study
Contrary to expectations, decreased average daily gain and food intake. Reduced plasma IGFBP-3, IGF-1, and insulin. Growth hormone dropped 23% with 60% reduction in pulse area.
Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia